Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Denali Therapeutics Inc (NQ: DNLI)
25.93 USD  -0.89 (-3.32%)
Official Closing Price  /  Updated: 4:00 PM EDT, Jul 10, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 168,700
Open 26.97
Bid (Size) 24.95 (1)
Ask (Size) 28.00 (10)
Prev. Close 26.82
Today's Range 25.83 - 27.04
52wk Range 12.39 - 30.41
Shares Outstanding 94,441,892
Dividend Yield N/A
Performance
YTD
+58.21%
+58.21%
1 Month
+0.78%
+0.78%
3 Month
+35.55%
+35.55%
6 Month
+38.74%
+38.74%
1 Year
+28.24%
+28.24%
Top News
More News
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
Tessera Therapeutics emerges from three years of stealth operations to pioneer Gene Writing™ as a new genome engineering technology and category of genetic medicine Read More
from PR Newswire
Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi
from GlobeNewswire News Releases
More News
Read More
Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity
from PR Newswire
Denali Therapeutics Announces Publication of Two New Papers Describing Its Blood-Brain Barrier Delivery Technology in Science Translational Medicine
from GlobeNewswire News Releases
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
from GlobeNewswire News Releases
Denali Therapeutics Provides Pipeline and Business Update in Response to the COVID-19 Pandemic
from GlobeNewswire News Releases
Flagship Pioneering Completes Raising a New $1.1 Billion Capital Pool
from PR Newswire
Denali Therapeutics Larger Than S&P 500 Component Nordstrom
category Stocks
from Market News Video
Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund
from Business Wire News Releases
Denali Therapeutics Reaches Analyst Target Price
category ETFs
from ETF Channel
Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X